Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Nova Mentis Welcomes Autism Behaviour Analyst to its Science Team
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is proud to welcome John Molinaro, a Board Certified Behaviour Analyst specializing in autism spectrum disorder therapy, to its Scientific Advisory Board.
温哥華，不列顛哥倫比亞省-(Newsfile Corp.-2022年5月12日)-Nova Mentis生命科學公司(CSE：NOVA)(FSE：HN3Q)(OTCQB：NMLSF)(“Nova”或“公司”)，一家生物技術公司在一流的基於裸蓋菇素的療法和神經炎性疾病的補充診斷方面處於全球領先地位，該公司自豪地歡迎專門從事自閉症譜系障礙治療的董事會認證行為分析師John Molinaro加入其科學諮詢委員會。
"Making advancements in challenging disorders such as autism and fragile x syndrome requires a team of experts who share information and innovative ideas. Mr. Molinaro will further strengthen NOVA's Scientific Advisory Board and help guide our leading-edge research and clinical endeavors to help find new diagnostic and treatment options for these conditions," stated Dr. Marvin S. Hausman MD, Chairman of NOVA's Scientific Advisory Board.
諾瓦公司科學顧問委員會主席馬文·S·豪斯曼博士説：“在自閉症和脆性X綜合徵等挑戰性疾病方面取得進展需要一支分享信息和創新想法的專家團隊。莫利納羅先生將進一步加強諾華公司的科學諮詢委員會，並幫助指導我們的前沿研究和臨牀努力，幫助找到針對這些疾病的新的診斷和治療選擇。”
John Molinaro is a Board Certified Behaviour Analyst (BCBA) with a Master's degree in Applied Behaviour Analysis, as well as a Bachelor's degree in Psychology. For more than 13 years, Mr. Molinaro has dedicated his life to supporting children, youth and adults challenged with physical and cognitive disabilities. Since 2015, Mr. Molinaro shifted his efforts primarily towards the autism community and started the Colours of the Spectrum ABA autism spectrum disorder (ASD) clinic in 2018. Mr. Molinaro and his team have supported hundreds of children and families with varying severities of ASD through one-on-one behaviour therapy and parent coaching.
約翰·莫利納羅是一名董事會認證行為分析師(BCBA)，擁有應用行為分析碩士學位和心理學學士學位。13年多來，莫利納羅先生畢生致力於支持有身體和認知障礙的兒童、青年和成年人。自2015年以來，Molinaro先生將他的努力主要轉向自閉症社區，並於2018年開始創建Spectrum ABA自閉症譜系障礙(ASD)診所的顏色。莫利納羅和他的團隊通過一對一的行為治療和家長輔導，支持了數百名患有不同程度自閉症的兒童和家庭。
NOVA is currently enrolling participants into its North American observational study that will examine the neuroinflammatory mRNA genetic profile contained within cheek cells and measure serotonin levels in patient saliva. The research objective is to develop a genetic neuroinflammatory and serotonin data bank that will help establish a "Diagnostic Index" - an objective set of tools that helps to differentiate subtypes of ASD and FXS, and to develop more accurate methods of diagnosis and treatment.
Nova目前正在招募參與者參加其北美觀察性研究，該研究將檢查頰細胞中包含的神經炎性mRNA基因圖譜，並測量患者唾液中的5-羥色胺水平。研究的目標是開發一個遺傳性神經炎和5-羥色胺數據庫，以幫助建立“診斷指數”--一套客觀的工具，幫助區分ASD和FXS的亞型，並開發更準確的診斷和治療方法。
Collected data will be analyzed using customized machine learning algorithms and used to guide design of upcoming clinical trials that will test the efficacy of psilocybin-based therapeutics in ASD and FXS. Patients enrolled in this observational study will have a high priority position to be enrolled in NOVA's planned psilocybin microdose clinical trials in Canada and the United States.
收集的數據將使用定製的機器學習算法進行分析，並用於指導即將進行的臨牀試驗的設計，這些試驗將測試基於裸蓋菇素的療法在ASD和FXS中的療效。參加這項觀察性研究的患者將優先參加Nova計劃在加拿大和美國進行的裸蓋菇素微劑量臨牀試驗。
For more information on this research, visit: novamentis.ca/autismstudy. To express your interest in participating in this study, please complete our enrollment form.
有關這項研究的更多信息，請訪問：novamentis.ca/autismStudy。為了表達您對參加本次學習的興趣，請填寫我們的報名錶。
About Nova Mentis Life Science Corp.
關於Nova Mentis生命科學公司
Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova is the first biotech company to achieve orphan drug designation in both the United States and European Union for the use of psilocybin in the treatment of Fragile X Syndrome (FXS).
Nova Mentis生命科學公司是一家總部位於加拿大的生物技術公司，在開發神經炎性疾病的診斷和基於裸蓋菇素的療法方面處於全球領先地位。Nova是第一家在美國和歐盟獲得使用裸蓋菇素治療脆性X綜合徵(FXS)的孤兒藥物指定的生物技術公司。
Our goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and FXS.
我們的目標是診斷和治療那些沒有滿足醫療需求的令人衰弱的慢性疾病，如自閉症譜系障礙(ASD)和FXS。
For further information on the Company, please visit or email info@novamentis.ca.
欲瞭解更多有關公司的信息，請訪問或發送電子郵件至info@novamentis.ca。
On Behalf of the Board
我謹代表董事會
Will Rascan, President & CEO
Nova Mentis Life Science Corp.
威爾·拉斯坎，總裁兼首席執行官
Nova Mentis生命科學公司
Phone: 778-819-0244
Toll Free: 1-833-542-5323
電話：778-819-0244
免費電話：1-833-542-5323
Twitter: @novamentislsc
Instagram: @novamentislsc
Facebook: @novamentislsc
推特：@novamentislsc
Instagram：@novamentislsc
臉書：@novamentislsc
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
加拿大證券交易所及其市場監管機構(該術語在加拿大證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。
This news release contains statements that constitute "forward-looking statements." Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
本新聞稿包含構成“前瞻性陳述”的陳述。此類前瞻性表述涉及已知和未知的風險、不確定性和其他因素，可能導致Nova Mentis生命科學公司的實際結果、業績或成就或行業發展與此類前瞻性表述明示或暗示的預期結果、業績或成就大不相同。前瞻性陳述是指不是歷史事實的陳述，通常但並非總是由“預期”、“計劃”、“預期”、“相信”、“打算”、“估計”、“項目”、“潛在”和類似的表述，或事件或條件“將”、“將”、“可能”、“可能”或“應該”發生。
To view the source version of this press release, please visit
要查看本新聞稿的源版本，請訪問
譯文內容由第三人軟體翻譯。